申请人:H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
公开号:US20160257712A1
公开(公告)日:2016-09-08
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.